KR102307278B1 - 신규 척추동물 세포 및 관심 폴리펩티드의 재조합적 발현 방법 - Google Patents

신규 척추동물 세포 및 관심 폴리펩티드의 재조합적 발현 방법 Download PDF

Info

Publication number
KR102307278B1
KR102307278B1 KR1020167032875A KR20167032875A KR102307278B1 KR 102307278 B1 KR102307278 B1 KR 102307278B1 KR 1020167032875 A KR1020167032875 A KR 1020167032875A KR 20167032875 A KR20167032875 A KR 20167032875A KR 102307278 B1 KR102307278 B1 KR 102307278B1
Authority
KR
South Korea
Prior art keywords
matriptase
cell
polypeptide
interest
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167032875A
Other languages
English (en)
Korean (ko)
Other versions
KR20160147919A (ko
Inventor
홀거 라욱스
산드린 로만드
우르술라 보덴도르프
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53682742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102307278(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20160147919A publication Critical patent/KR20160147919A/ko
Application granted granted Critical
Publication of KR102307278B1 publication Critical patent/KR102307278B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
KR1020167032875A 2014-04-29 2015-04-29 신규 척추동물 세포 및 관심 폴리펩티드의 재조합적 발현 방법 Active KR102307278B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461985589P 2014-04-29 2014-04-29
US61/985,589 2014-04-29
US201461994310P 2014-05-16 2014-05-16
US61/994,310 2014-05-16
PCT/IB2015/053110 WO2015166427A2 (en) 2014-04-29 2015-04-29 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest

Publications (2)

Publication Number Publication Date
KR20160147919A KR20160147919A (ko) 2016-12-23
KR102307278B1 true KR102307278B1 (ko) 2021-09-30

Family

ID=53682742

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032875A Active KR102307278B1 (ko) 2014-04-29 2015-04-29 신규 척추동물 세포 및 관심 폴리펩티드의 재조합적 발현 방법

Country Status (17)

Country Link
US (2) US11512335B2 (enExample)
EP (3) EP4332231A3 (enExample)
JP (1) JP6636453B2 (enExample)
KR (1) KR102307278B1 (enExample)
CN (1) CN106255749A (enExample)
AU (1) AU2015254913B2 (enExample)
CA (1) CA2947198C (enExample)
DK (2) DK3536776T5 (enExample)
ES (2) ES2968879T3 (enExample)
IL (1) IL248184B (enExample)
LT (2) LT3137595T (enExample)
MX (1) MX368664B (enExample)
PL (2) PL3137595T3 (enExample)
PT (2) PT3137595T (enExample)
RU (1) RU2710726C2 (enExample)
SG (1) SG11201608358VA (enExample)
WO (1) WO2015166427A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4332231A3 (en) 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
AU2018290281B2 (en) 2017-06-22 2021-12-16 Vertex Pharmaceuticals Incorporated Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
WO2020081328A1 (en) * 2018-10-15 2020-04-23 The Regents Of The University Of California Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins
PE20221416A1 (es) 2019-09-18 2022-09-20 Novartis Ag Proteinas de fusion nkg2d y sus usos
US20210244821A1 (en) 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
EP4150085A1 (en) * 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
CN115551519A (zh) * 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
EP4526462A1 (en) * 2022-05-19 2025-03-26 Novartis AG Improved protein production using mirna technology

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
AU572108B2 (en) 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
US5371198A (en) * 1991-12-16 1994-12-06 Novo Nordisk A/S Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU2001278488A1 (en) 2000-07-25 2002-02-05 Bayer Aktiengesellschaft Regulation of human matriptase-like serine protease
CN100513414C (zh) * 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
MXPA05003493A (es) * 2002-10-02 2005-09-30 Catalyst Biosciences Metodos para generar y seleccionar proteasas con especificidad alterada.
ATE399872T1 (de) 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
CN102443627B (zh) * 2004-08-10 2014-10-29 加的夫生物学有限公司 用于乳腺癌的预后的试剂盒
ATE504602T1 (de) 2004-12-20 2011-04-15 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
ES2546086T3 (es) 2007-12-21 2015-09-18 Novartis Ag Sistema de selección en un cultivo de células eucariotas basado en un gen receptor de folato unido a la membrana
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
CA2753814C (en) 2009-02-27 2018-07-31 Novartis Ag Novel selection vectors and methods of selecting eukaryotic host cells
US8722964B2 (en) * 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
PT2563904E (pt) 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
ES2676412T3 (es) 2011-06-02 2018-07-19 Socpra Sciences Santé Et Humaines S.E.C. Inhibidores de matriptasa y usos de los mismos contra infecciones por ortomixovirus
CN110078827A (zh) * 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
SG11201408554QA (en) * 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
EP4332231A3 (en) 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Also Published As

Publication number Publication date
EP3137595B1 (en) 2019-03-13
ES2968879T3 (es) 2024-05-14
CN106255749A (zh) 2016-12-21
IL248184B (en) 2021-03-25
IL248184A0 (en) 2016-11-30
EP3536776A1 (en) 2019-09-11
AU2015254913A1 (en) 2016-10-27
DK3536776T3 (da) 2024-01-15
JP6636453B2 (ja) 2020-01-29
DK3137595T3 (da) 2019-06-17
EP4332231A3 (en) 2024-05-29
PL3536776T3 (pl) 2024-03-25
MX368664B (es) 2019-10-10
LT3137595T (lt) 2019-06-25
WO2015166427A2 (en) 2015-11-05
BR112016024534A2 (pt) 2017-10-10
AU2015254913B2 (en) 2018-05-17
RU2016145928A (ru) 2018-05-29
KR20160147919A (ko) 2016-12-23
RU2016145928A3 (enExample) 2018-12-26
PT3137595T (pt) 2019-06-19
JP2017514484A (ja) 2017-06-08
EP4332231A2 (en) 2024-03-06
DK3536776T5 (da) 2024-09-02
CA2947198A1 (en) 2015-11-05
PL3137595T3 (pl) 2019-09-30
US20170044587A1 (en) 2017-02-16
SG11201608358VA (en) 2016-11-29
RU2710726C2 (ru) 2020-01-10
LT3536776T (lt) 2024-01-25
WO2015166427A3 (en) 2016-01-14
MX2016014222A (es) 2017-05-04
US11512335B2 (en) 2022-11-29
US20230323419A1 (en) 2023-10-12
ES2731246T3 (es) 2019-11-14
EP3137595A2 (en) 2017-03-08
PT3536776T (pt) 2024-01-12
EP3536776B1 (en) 2023-10-25
CA2947198C (en) 2023-01-17

Similar Documents

Publication Publication Date Title
US20230323419A1 (en) Vertebrate cells and methods for recombinantly expressing a polypeptide of interest
KR102288857B1 (ko) 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법
EP3083677B1 (en) Novel eukaryotic cells and methods for recombinantly expressing a product of interest
BR112016024534B1 (pt) Métodos para produzir de forma recombinante um polipeptídeo de interesse, para produzir uma célula de vertebrado isolada, e para selecionar uma célula, bem como uso de uma célula de vertebrado
US20250313878A1 (en) IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5